Why Is Spravato So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed Spravato (esketamine) nasal spray for treatment-resistant depression, you may be shocked to discover how hard it is to actually access treatment. Unlike most medications you simply pick up at a pharmacy, Spravato comes with a web of requirements, restrictions, and limited locations that make it feel almost impossible to get — even when you have a valid prescription.

The good news: Spravato is not on the FDA's drug shortage list. The bad news: access barriers make it nearly as difficult to obtain as if it were. Here's everything you need to know about why Spravato is so hard to find — and what patients can do about it in 2026.

Is Spravato Actually in a Shortage?

No — as of 2026, Spravato is not on the FDA's official drug shortage list. The medication itself is being manufactured and distributed by Janssen Pharmaceuticals (a Johnson & Johnson company) without supply interruptions.

However, a drug doesn't need to be in a formal shortage for patients to struggle to get it. Spravato's access problems are structural — built into the very way the drug is required to be dispensed and administered. These barriers affect patients across the country, regardless of whether supply is adequate.

What Is the REMS Program and Why Does It Restrict Access?

The single biggest reason Spravato is hard to access is the SPRAVATO REMS — a Risk Evaluation and Mitigation Strategy program mandated by the FDA. Because esketamine is a Schedule III controlled substance with a risk of sedation, dissociation, respiratory depression, and potential for abuse, the FDA requires that every dose be administered in a certified healthcare setting under direct supervision.

Here's what the REMS program means in practice:

You cannot take Spravato home. It must be dispensed and used at a REMS-certified facility.

You must be monitored for at least 2 hours after each treatment session.

The clinic, pharmacy, and patient must all be enrolled in the REMS program.

You need someone to drive you home after every session — you cannot drive until the next day after a restful sleep.

This means finding a regular pharmacy that stocks Spravato is not an option. You need to locate a certified treatment center near you, and those aren't found in every town.

Limited Number of Certified Treatment Centers

Because of the REMS requirements, Spravato is only available at certified outpatient or inpatient healthcare settings. These include psychiatric clinics, behavioral health centers, some hospital outpatient departments, and specialized ketamine/esketamine treatment centers.

The problem is geography. Certified Spravato treatment centers tend to be concentrated in urban and suburban areas. Patients in rural communities may face drives of 50, 100, or even more miles to reach the nearest certified facility — and they need to make that trip twice weekly during the 4-week induction phase. That's a significant logistical burden that prevents many people from ever starting or completing treatment.

Insurance Prior Authorization: A Major Barrier

Even if you find a certified treatment center nearby, insurance access is the next hurdle. Every major insurer — Aetna, Cigna, United Healthcare, Blue Cross Blue Shield, Medicare, and Medicaid — requires prior authorization before covering Spravato. The approval process typically requires:

Documentation of a TRD or MDD with suicidal ideation diagnosis

Evidence of failed trials of at least 2 oral antidepressants (adequate dose and duration)

Prescription by or in consultation with a psychiatrist

No severe hepatic impairment (Child-Pugh class C)

The prior authorization process can take 1 to 4 weeks, adding another layer of delay for patients who may already be in crisis.

The Cost Problem: Spravato Is Extremely Expensive Without Insurance

Without insurance, Spravato costs approximately $600 to $1,200 per treatment session, depending on the dose and clinic fees. The first month of treatment — which involves twice-weekly sessions — can total $8,200 or more. For patients who are uninsured or underinsured, this cost is simply out of reach, no matter how many certified centers are nearby.

Janssen does offer the Spravato withMe Savings Program, which can reduce medication costs to as little as $10 per session for eligible commercially insured patients (with an $8,150 maximum annual benefit). But uninsured patients and those on Medicare or Medicaid may still face significant out-of-pocket costs.

Why Spravato Can't Be Filled at a Regular Pharmacy

Unlike most prescription drugs, Spravato is not dispensed through your local pharmacy. You won't find it at CVS, Walgreens, or any retail chain. The drug is distributed through a specialty pharmacy pathway to certified healthcare facilities, and it is administered on-site. The medication stays at the clinic — it never goes home with you.

This is a fundamentally different model than most medications. Calling pharmacies to check stock is irrelevant — what matters is finding a certified treatment center that accepts your insurance and has appointment availability.

The Time Commitment Creates Real Barriers

Spravato treatment requires a serious time commitment, especially during the induction phase. Patients must attend twice-weekly in-clinic sessions and remain under observation for at least 2 hours after each dose. During and after the session, patients cannot drive, making transportation another practical barrier.

For patients who work full-time, have childcare responsibilities, or rely on public transportation, these requirements can make consistent treatment nearly impossible — even when a certified center exists nearby.

What You Can Do If You're Having Trouble Accessing Spravato

Here are practical steps to overcome access barriers:

Use the official SPRAVATO treatment center locator at spravato.com to find a certified facility near you.

Ask your prescribing psychiatrist to help coordinate with a certified treatment center and navigate the prior authorization process.

Apply for the Spravato withMe Savings Program if you have commercial insurance to reduce your per-session medication cost.

Appeal insurance denials. Studies show that roughly 30% of initial prior authorization denials are overturned on appeal when patients submit thorough documentation.

Discuss alternatives with your doctor if Spravato remains inaccessible. IV ketamine (off-label), TMS, and Auvelity are other options for treatment-resistant depression.

How medfinder Can Help

While Spravato itself is not available at regular pharmacies, patients dealing with all types of hard-to-find medications — including those that support their mental health treatment — can benefit from medfinder. medfinder calls pharmacies near you to find which ones can fill your prescription, saving you the time and stress of calling around yourself.

Read more about practical strategies in our guide: How to Find Spravato In Stock Near You (Tools + Tips).

The Bottom Line

Spravato is hard to access not because of a supply shortage, but because of structural barriers: REMS program requirements that limit where it can be given, a limited number of certified treatment centers (especially in rural areas), expensive out-of-pocket costs, and insurance prior authorization hurdles. For patients living with treatment-resistant depression, these aren't minor inconveniences — they're serious obstacles to potentially life-saving treatment.

If Spravato access remains out of reach, be sure to explore our overview of alternatives to Spravato for treatment-resistant depression with your doctor.